A5040423978- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Breast Cancer Treatment Studies
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Cancer survivorship and care
- Monoclonal and Polyclonal Antibodies Research
- Chemokine receptors and signaling
- Cancer, Lipids, and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Bioinformatics and Genomic Networks
- Lung Cancer Treatments and Mutations
- Gene expression and cancer classification
- Ferroptosis and cancer prognosis
The University of Texas MD Anderson Cancer Center
2015-2024
Scripps MD Anderson Cancer Center
2020
The University of Adelaide
2020
Brigham Young University
2016-2020
The University of Notre Dame Australia
2020
University of Notre Dame
2020
University of British Columbia
2020
Baylor College of Medicine
2016
Anderson University - South Carolina
2015
Welch Foundation
2015
We tested the hypothesis that level of circulating tumor cells can predict survival in metastatic breast cancer.In a prospective, multicenter study, we 177 patients with measurable cancer for levels both before were to start new line treatment and at first follow-up visit. The progression disease or response was determined use standard imaging studies participating centers.Outcomes assessed according baseline, started disease. Patients training set equal higher than 5 per 7.5 ml whole blood,...
Metastatic breast cancer (MBC) is incurable; its treatment palliative. We investigated whether the presence of circulating tumor cells (CTCs) predicts efficacy, progression-free survival (PFS), and overall (OS) in patients with newly diagnosed MBC who were about to start first-line therapy.One hundred seventy-seven measurable enrolled onto a prospective study. Eighty-three 177 entering treatment, these are focus this analysis. CTCs from 7.5 mL whole blood drawn before initiation (baseline)...
We treated seven patients who had progressive hairy-cell leukemia with daily doses of 3 million units partially pure alpha (leukocyte) interferon by the intramuscular route. Three a complete remission, and four partial according to strict criteria for response. After treatment, bone-marrow aspirates showed an absence cells in three 5 per cent or fewer others. Normalization subnormal peripheral-blood values occurred six anemia, granulocytopenia, thrombocytopenia. Remissions have been...
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics denileukin diftitox (DAB 389 IL-2, Ontak [Ligand Phar-maceuticals Inc, San Diego, CA]) in patients with stage Ib IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions. PATIENTS AND METHODS: Patients biopsy-proven CTCL that expressed CD25 on ≥ 20% lymphocytes were assigned one two dose levels (9 or 18 μg/kg/d) administered 5 consecutive days...
Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance leading to effective immune responses cancer in humans. A phase I trial was conducted test the safety of CP-675,206.Thirty-nine patients solid malignancies (melanoma, n = 34; renal cell, 4; colon, 1) received an intravenous (IV) infusion CP-675,206 at seven dose levels. The primary objective determine maximum-tolerated and...
Journal Article Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study Get access Gabriel Lopez-Berestein, Lopez-Berestein Search other works by this author on: Oxford Academic PubMed Google Scholar Victor Fainstein, Fainstein Roy Hopfer, Hopfer Kapil Mehta, Mehta Margaret P. Sullivan, Sullivan Michael Keating, Keating G. Rosenblum, Rosenblum Reeta Mario Luna, Luna Evan M. Hersh, Hersh ... Show more James Reuben, Reuben Rudolph...
Abstract Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable selectively expressed by breast cancer stem cells (BCSCs). Reparixin investigational allosteric inhibitor of chemokine receptors and 2 (CXCR1/2), demonstrates activity against BCSCs in human xenografts. This phase Ib clinical trial examined dose, safety, pharmacokinetics paclitaxel plus reparixin therapy, explored effects on patients with metastatic (MBC) (trial registration ID: NCT02001974). Experimental Design:...
Despite exciting progress in the understanding of breast cancer development and progression, novel therapeutic strategies, remains second leading cause cancer-related death women, with a yearly toll more than 40,000 deaths United States
Abstract Introduction Circulating tumor cells (CTCs) represent an independent predictor of outcome in patients with metastatic breast cancer (MBC). We assessed the prognostic impact CTCs according to different first-line systemic treatments, and explored their potential predictive value MBC patients. Methods retrospectively evaluated 235 newly diagnosed patients, treated at University Texas MD Anderson Cancer Center. All had a baseline CTC assessment performed CellSearch ® . Progression-free...
Currently, there is extensive information about circulating tumor cells (CTC) and their prognostic value; however, little known other characteristics of these cells. In this prospective study, we assessed the gene transcripts epithelial-to-mesenchymal transition-inducing transcription factors (EMT-TF) cancer stem cell (CSC) features in patients with HER2(+) metastatic breast (MBC). Epithelial were enriched from peripheral blood mononuclear (PBMC) using antibody-coated anti-CD326 antibody...
The detection of CTCs prior to and during therapy is an independent strong prognostic marker, it predictive poor treatment outcome. A major challenge that different technologies are available for isolation characterization in peripheral blood (PB). We compare the CellSearch system AdnaTest BreastCancer Select/Detect, evaluate extent these assays differ their ability detect PB MBC patients. 7.5 ml were isolated enumerated using CellSearch, before new treatment. Two cutoff values ≥2 ≥5...